Ommaya Reservoir Placement for Brain Tumor Biomarker Access
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT04692337
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intra-operative Ommaya Reservoir placement — PROCEDUREAn Ommaya reservoir is a small device implanted under the scalp that enables percutaneous access to cerebrospinal fluid.
Study Details
The purpose of this study is to determine the safety and feasibility of intra-operative Ommaya Reservoir placement during a clinically indicated operation for brain tumor. The Ommaya reservoir will facilitate a longitudinal access to cerebrospinal fluid (CSF) for analysis of potential biomarkers for brain tumor research and individualized monitoring.
Key Dates
- Start date
- Jan 15, 2021
- Status verified
- Feb 2026
- Primary completion
- Feb 28, 2027
- Completion
- Feb 28, 2027
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Ommaya Reservoir placementSubjects undergoing surgery for a confirmed or suspected brain tumor will have an Ommaya Reservoir placed at the time of surgery.
Primary Outcome Measure
Collection of serial CSF samples for biobanking and biomarker discovery and validation - proportion of patients [ Time Frame: Through study completion, approximately 42 days ]
Central Contacts
- Essa Sharif507-538-6342
- Clinical Trials Referral Office855-776-0015
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Terry C. Burns, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)Recruiting · GT Medical Technologies, Inc. · Phoenix, Arizona
- Extracellular Impact of Ultrasound-induced Blood-brain Barrier DisruptionRecruiting · Mayo Clinic · Rochester, Minnesota
- A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated GlioblastomaPHASE3 · Recruiting · Ivy Brain Tumor Center · Birmingham, Alabama
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossPHASE1/PHASE2 · Recruiting · Tango Therapeutics, Inc. · Scottsdale, Arizona